SCHEMBL6132432

SCHEMBL6132432

CCOC(=O)c1ccc(N2CCN(C3CCC(OCCCCCCCCOC)CC3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
POLB P06746 3/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
ALOX15 P16050 1/20 0.40
HSP90AA1 P07900 2/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 1/20 0.39
FDFT1 P37268 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132359 1.00 ALDH1A1 (0.47) ALDH1A1POLBMEN1KMT2ASMN1; SMN2
SCHEMBL6132246 0.91 HTT (0.44) ALDH1A1POLBMEN1KMT2ASMN1; SMN2
SCHEMBL6132393 0.91 HTT (0.44) ALDH1A1POLBMEN1KMT2ASMN1; SMN2
SCHEMBL6132214 0.88 MEN1 (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL6134438 0.88 MEN1 (0.44) ALDH1A1POLBMEN1KMT2ASMN1; SMN2
SCHEMBL6132733 0.87 MEN1 (0.45) ALDH1A1MEN1KMT2AMAPTTSHR
SCHEMBL6132535 0.87 MEN1 (0.45) ALDH1A1MEN1KMT2AMAPTTSHR
SCHEMBL63474 0.86 ALDH1A1 (0.59) ALDH1A1POLBMEN1KMT2ASMN1; SMN2
SCHEMBL6132416 0.85 ALDH1A1 (0.53) ALDH1A1POLBMEN1KMT2ASMN1; SMN2
SCHEMBL6134754 0.85 HRH3 (0.45) ALDH1A1POLBKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed
EP-1259535-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060846-A1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 ALDH1A1 4718/4885POLB 1311/4885MEN1 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.